"Revolutionizing Pain Management: The Rise of Non-Steroidal Anti-Inflammatories"

AG5, a novel non-steroidal anti-inflammatory compound developed in response to the COVID-19 pandemic, effectively inhibits cytokine storms while preserving innate immunity, offering a safer alternative to corticosteroids like dexamethasone. It has shown potential in treating various inflammatory diseases and in CAR T-cell therapy, with in vitro and animal testing demonstrating its efficacy. AG5 is expected to be useful in the treatment of chronic inflammatory diseases and is currently in the preclinical stage, with plans for a Phase I/II clinical study in patients with fatty liver disease by 2024.